Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 9OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × olaratumab × Clear all
NCT03985722 2023-03-27

OLATRASTS

Grupo Espanol de Investigacion en Sarcomas

Phase 1 Unknown
28 enrolled
Sarcoma

Sarcoma

NCT03437070 2019-03-18

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

University of Miami

Phase 1 Withdrawn
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡